This report analyzes the worldwide markets for Anticoagulants in Millions of US$. The major product segments analyzed are Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 51 companies including many key and niche players worldwide such as AstraZeneca PLC, Barr Laboratories Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, and Sanofi-Aventis. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTICOAGULANTS									MCP-1205
A GLOBAL STRATEGIC BUSINESS REPORT


                                             CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-3
      Product Definitions And Scope Of Study                            I-3


 II. EXECUTIVE SUMMARY

  1. Worldwide Anticoagulants Market                                    II-1
      Global Market Overview                                            II-1
      Current and Future Scenario                                       II-1
      Major Markets - Products                                          II-1
       Injectable Anticoagulants - On An Up Trend                       II-1
       Low Molecular Weight Heparins - Ruling the Roost                 II-1
      Major Markets - Regional                                          II-2
       United States - The Largest Market                               II-2
       Europe - The Second Largest Market                               II-2

  2. Industry Overview                                                  II-3
      The Pharmaceuticals Industry                                      II-3
       Industry Framework                                               II-3
       Regulatory Price Controls - Present and Future                   II-3
       Consolidations Driving the Industry                              II-4
       Patent Expiries Giving Way to Generic Drugs                      II-4
      Anticoagulants Sector                                             II-4
       A Snapshot of Available Therapies                                II-4
        An Insight into Currently Available Antithrombotic Drugs        II-5
       Weaknesses of Available Therapies                                II-5
       Forces Driving the Market                                        II-6
      Oral Anticoagulants Market                                        II-6
      Injectable Anticoagulants Market                                  II-6
       Heparin Market                                                   II-6
       LMWH Market                                                      II-7

  3. Market Dynamics                                                    II-8
      Drug Advancements Drive Anticoagulant Market                      II-8
      Niche Markets - The New Target for Drug Makers                    II-8
      An Opportunity to Grow Further                                    II-8
      Geriatric Patients - At High Risk of Blood Clots                  II-8
      Improved Anticoagulant Agents for Children Group                  II-9
      Growing Demand for Self-Testing                                   II-9
      LMWHs Eases Outpatient Management                                 II-9
      Concern Over Underutilization of Warfarin                         II-9
      Anticoagulants to Lose UA/AMI Markets to Antiplatelets            II-10
      Influx of New Drugs: Invigorates the Market                       II-10
      Novel Heparins: Enhances Market Potential                         II-10
      Anticoagulant Therapy During Pregnancy Improves Outcomes          II-10
      New Therapies: Need of the Hour                                   II-11
      Anticoagulant Therapy in IPF: Reduces Mortality Risk              II-11
      Failure of Exanta                                                 II-11

  4. Product Overview                                                   II-12
      Introduction to Anticoagulants                                    II-12
       Evolution of Anticoagulants                                      II-12
       Blood Coagulation - A Major Concern                              II-12
       Anticoagulants Disrupts Metastatic Events                        II-13
       The Coagulation Cascade                                          II-13
        Coagulation Factors Found in the Coagulation Cascade            II-13
       Precautions                                                      II-13
       Side Effects                                                     II-14
       Hemorrhagic Symptoms and Side Effects                            II-14
       Impediments                                                      II-15
       Potential Candidates for Anticoagulation                         II-15
       Alternative Therapies to Anticoagulants                          II-15
       Thrombolytics - Another Major Solution for Thrombosis            II-15
      Anticoagulants Drug Class                                         II-16
       Oral Anticoagulants                                              II-16
        Oral Anticoagulants Induces Calcification                       II-16
        Warfarin                                                        II-16
         Advantages and Alternatives                                    II-16
         Side Effects                                                   II-17
         Limitations                                                    II-17
        Coumadin                                                        II-17
       Injectable Anticoagulants                                        II-18
        Heparin - The Backbone of Injectable Anticoagulants             II-18
        Unfractionated Heparin                                          II-19
         Advantages and Alternatives                                    II-19
         Limitations                                                    II-19
        Low Molecular Weight Heparins                                   II-20
        Costs                                                           II-21
        Impediments                                                     II-22
         Lovenox/Clexane (enoxaparin)                                   II-22
          Approved Indications for Lovenox:                             II-22
          Advantages and Alternatives                                   II-22
         Fragmin (dalteparin)                                           II-23
          Approved Indications for Fragmin Use:                         II-23
          Contradictions                                                II-23
          Precautions                                                   II-24
         Fraxiparine (nadroparin)                                       II-24
         Innohep (tinzaparin)                                           II-25
          Contraindications                                             II-25
          Side Effects                                                  II-26
           Other Serious Adverse Events Associated with Innohep         II-26
          Precautions                                                   II-26
         Normiflo (ardeparin)                                           II-27
         Clivarine (reviparin)                                          II-27
          Summary of Available LMWHs                                    II-27
        Non-Heparin Injectables                                         II-27
         Arixtra (fondaparinux)                                         II-27
          Contraindications                                             II-28
          Market and Market Participants                                II-28
         Angiomax (bivalirudin)                                         II-28
          Advantages                                                    II-29
          Contraindications                                             II-29
          Side Effects                                                  II-29
         Argatroban/ Novastan                                           II-29
          Side Effects                                                  II-30
          Precautions                                                   II-30
         Refludan (lepirudin)                                           II-30
         Orgaran (danaparoid sodium)                                    II-30
          Contraindications                                             II-31
          Side Effects                                                  II-31
          Caution                                                       II-32
          Precaution                                                    II-32
         A Comparative Analysis of Various Direct Thrombin Inhibitors   II-32
       Other Anticoagulants                                             II-32
        Lithium Heparin                                                 II-32
        EDTA                                                            II-33
        Citrate                                                         II-33
        Oxalate                                                         II-33

  5. A Comparative Study of Anticoagulant Therapies                     II-34

  A Comparative Study of Warfarin Against LMWHs                         II-34
      A Comparative Study of LMWH Against UFH                           II-35
      A Comparative Study of Heparin Against Angiomax                   II-36
      A Comparative Study of Arixtra Against UFH and LMWH               II-36
      A Comparative Study of Angiomax Against UFH and LMWH              II-36

  6. Areas of Indication                                                II-37
      Indications for Anticoagulant Use                                 II-37
       Venous/DVT Thrombosis Indications                                II-37
        Venous Thromboembolism (VTE)                                    II-37
         Deep Vein Thrombosis (DVT)                                     II-37
         Pulmonary Embolism (PE)                                        II-39
        Orthopedic (Hip or Knee Replacement) Surgery                    II-40
        General Surgery                                                 II-41
        Cancer                                                          II-42
       Arterial Thrombosis Indications                                  II-42
        Arterial Thrombosis                                             II-42
         Acute Coronary Syndromes (ACS)                                 II-43
          Atrial Fibrillation (AF)                                      II-43
          Unstable Angina (UA)                                          II-44
         List of Approved Anticoagulants for Unstable Angina            II-45
          Myocardial Infraction (MI)                                    II-45
          Non-ST Segment Elevation MI                                   II-45
          List of Approved Anticoagulants for Non-ST Segment
           Elevation Myocardial Infraction                              II-46
         Percutaneous Transluminal Coronary Angioplasty (PTCA)          II-46
          List of Approved Anticoagulants for Angioplasty Procedures    II-47
       Heparin Induced Thrombocytopenia (HIT) Indications               II-47
        HIT Type I                                                      II-47
        HIT Type II                                                     II-48
        Heparin Induced Thrombocytopenia with Thrombosis (HITTS)        II-49
       Other Indications                                                II-49
        Hemodialysis                                                    II-49

  7. Drug Development Pipeline                                          II-50
      Select Anticoagulants Under Pipeline                              II-50
      Idraparinux - Sanofi-Aventis                                      II-50
      0673 - Sanofi-Aventis                                             II-51
      BIBR1048MS - Boehringer Ingelheim                                 II-51

  8. Product Introductions                                              II-52
      Boehringer Receives EU Approval for Pradaxa                       II-52
      Sanofi-Aventis Receives Approval for Clexane(R) in Japan            II-52
      ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay II-52
      Lannett Obtains US FDA Approval for Dipyridamole Tablets          II-52
      Kimball Introduces New Pharmacogenetic Test                       II-52
      Roche Launches an Improved Point-of-Care Anticoagulation
       Monitoring System                                                II-53
      Danish Agency Grants Approval for Anticoagulant Clinical Trials   II-53
      EMEA Approves ARIXTRA(R) of GlaxoSmithKline                         II-53
      FDA Approves ANDAs of PLIVA                                       II-53
      FDA Approves ARIXTRA Injection of GSK                             II-53
      Japanese Ministry Approves Arixtra of GSK                         II-54
      Eisai Obtains FDA Approval for Fragmin                            II-54
      Sanofi-Aventis' Lovenox(R) Obtains FDA Approval for Acute
       Cardiac Care                                                     II-54
      Zydus Cadila's Warfarin Secures Approval from US FDA              II-54
      Momenta Pharmaceuticals Seeks Approval for M-Enoxaparin           II-55
      Mitsubishi Pharma Releases Argatroban in Europe                   II-55
      Regado Develops Anticoagulant                                     II-55

  9. Recent Industry Activity                                           II-56
      PAION Acquires CeNes Pharmaceuticals                              II-56
      PAION Announces Acquisition of Global Rights to Trigen's
       flovagatran                                                      II-56
      Biological E Collaborates with Choncept and Heparinex             II-56
      Bayer's Market Expansion                                          II-56
      B. Braun Recalls Heparin Sodium Based Injection Solutions         II-56
      Baxter Recalls Heparin Sodium Vials                               II-57
      Celgene Acquires Pharmion                                         II-57
      BMS Collaborates with Pfizer                                      II-57
      Medicines Company Reacquires European Rights for Angiox           II-58
      HemoSense and LabCorp Sign Agreement for Supply of INRatio System II-58
      Sanofi-Aventis Acquires Rights for Panaldine from Daiichi         II-58
      Alchemia Inks Marketing Alliance with Dr Reddy's for Heparin      II-59
      Inverness Announces Acquisition of HemoSense                      II-59
      ev3, FoxHollow Complete Merger                                    II-59
      Osmetech Signs Licensing Agreement with Marshfield Clinic         II-59
      Mitsubishi and Tanabe Agree to Merge                              II-60
      Artisan and A-Bio Form Alliance                                   II-60
      Archemix and Nuvelo Announces Expansion of Alliance               II-60
      American Capital Acquires Scientific Protein Laboratories' One
       Stop Buyout                                                     II-60
      Bristol-Myers to Start New Facility in Massachusetts              II-61
      AstraZeneca Stops Development of Exanta                           II-61
      Pfizer Enters into Agreement with BPC                             II-61
      AstraZeneca Pacts with Targacept                                  II-61
      GlaxoSmithKline Acquires ID Biomedical                            II-61
      Direct Capital Buys Stake in NZP                                  II-61
      Archemix and Nuvelo Stop Development of ARC183                    II-61
      Novartis Purchases Bristol-Myers' US/Canadian Consumer
       Medicine Operations                                              II-61
      Akers Pacts with Cardinal Health                                  II-62

  10. Focus on Select Global Players                                    II-63
      AstraZeneca PLC (UK)                                              II-63
      Barr Laboratories Inc (USA)                                       II-63
      Bristol-Myers Squibb Company (USA)                                II-63
      Celgene Corporation (USA)                                         II-64
      GlaxoSmithKline plc (UK)                                          II-64
      Mitsubishi Tanabe Pharma Corporation (Japan)                      II-64
      Pfizer Inc (USA)                                                  II-64
      Sanofi-Aventis (France)                                           II-65

  11. Global Market Perspective                                         II-66
      Table 1: World Recent Past, Current & Future Analysis for
      Anticoagulants by Geographic Region/Country - US, Japan,
      Europe, and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2000 through
      2010 (includes corresponding Graph/Chart)                         II-66

      Table 2: World Long-term Projections for Anticoagulants by
      Geographic Region/Country - US, Japan, Europe, and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-67

      Table 3: World 10-Year Perspective for Anticoagulants by
      Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Japan, Europe, and Rest of World Markets for
      Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)      II-68

      Table 4: World Recent Past, Current & Future Analysis for Oral
      Anticoagulants by Geographic Region/ Country - US, Japan,
      Europe, and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2000 through
      2010 (includes corresponding Graph/Chart)                         II-69

      Table 5: World Long-term Projections for Oral Anticoagulants
      by Geographic Region/Country - US, Japan, Europe, and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-70

      Table 6: World 10-Year Perspective for Oral Anticoagulants by
      Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Japan, Europe, and Rest of World Markets for
      Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)      II-71

      Table 7: World Recent Past, Current & Future Analysis for
      Injectable Anticoagulants by Geographic Region/Country - US,
      Japan, Europe, and Rest of World Markets Independently
      Analyzed with Annual Sales Figures in US$ Million for Years
      2000 through 2010 (includes corresponding Graph/Chart)            II-72

      Table 8: World Long-term Projections for Injectable
      Anticoagulants by Geographic Region/Country - US, Japan,
      Europe, and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2011 through
      2015 (includes corresponding Graph/Chart)                         II-73

      Table 9: World 10-Year Perspective for Injectable
      Anticoagulants by Geographic Region/Country - Percentage
      Breakdown of Dollar Sales for US, Japan, Europe, and Rest of
      World Markets for Years 2003, 2008 & 2012 (includes
      corresponding Graph/Chart)                                        II-74

      Table 10: World Recent Past, Current & Future Analysis for
      Injectable Anticoagulants by Product Segment - Unfractionated
      Heparin and Low Molecular Weight Heparin Markets Independently
      Analyzed with Annual Sales Figures in US$ Million for Years
      2000 through 2010 (includes corresponding Graph/Chart)            II-75

      Table 11: World Long-term Projections for Injectable
      Anticoagulants by Product Segment - Unfractionated Heparin and
      Low Molecular Weight Heparin Markets Independently Analyzed
      with Annual Sales Figures in US$ Million for Years 2011
      through 2015 (includes corresponding Graph/Chart)                 II-75

      Table 12: World 10-Year Perspective for Injectable
      Anticoagulants by Product Segment - Percentage Breakdown of
      Dollar Sales for Unfractionated Heparin and Low Molecular
      Weight Heparin Markets for the Years 2003, 2008 & 2012            II-76

      Table 13: World Recent Past, Current & Future Analysis for
      Unfractionated Heparin by Geographic Region/Country - US,
      Japan, Europe, and Rest of World Markets Independently
      Analyzed with Annual Sales Figures in US$ Million for Years
      2000 through 2010 (includes corresponding Graph/Chart)            II-77

      Table 14: World Long-term Projections for Unfractionated
      Heparin by Geographic Region/Country - US, Japan, Europe, and
      Rest of World Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-78

      Table 15: World 10-Year Perspective for Unfractionated Heparin
      by Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Japan, Europe, and Rest of World Markets for
      Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)      II-79

      Table 16: World Recent Past, Current & Future Analysis for Low
      Molecular Weight Heparin s by Geographic Region/Country - US,
      Japan, Europe, and Rest of World Markets Independently
      Analyzed with Annual Sales Figures in US$ Million for Years
      2000 through 2010 (includes corresponding Graph/Chart)            II-80

      Table 17: World Long-term Projections for Low Molecular Weight
      Heparin by Geographic Region / Country - US, Japan, Europe,
      and Rest of World Markets Independently Analyzed with Annual
      Sales Figures in US$ Million for Years 2011 through 2015
      (includes corresponding Graph/Chart)                              II-81

      Table 18: World 10-Year Perspective for Low Molecular Weight
      Heparin by Geographic Region/Country - Percentage Breakdown of
      Dollar Sales for US, Japan, Europe, and Rest of World Markets
      for Years 2003, 2008 & 2012 (includes corresponding
      Graph/Chart)                                                      II-82


III. MARKET

  1. The United States                                                  III-1
      A. Market Overview                                                III-1
        Outlook                                                         III-1
        Atrial Fibrillation - A Key Risk Factor                         III-1
        Regulatory Route to the US Market                               III-1
        Price Controls                                                  III-2
        US Anticoagulants Market                                        III-2
         US Heparin Market                                              III-2
         Hinging on Market Opportunities                                III-3
         Generics - Threatening Branded Anticoagulants                  III-3
        List of Patent Protected Anticoagulants in the US               III-4
        Ignorance - A Major Hindrance                                   III-4
        Future Challenges and Growth Drivers                            III-4
        US Emerging Anticoagulant Market                                III-4
         US Emerging Anticoagulants Market: Products in the Pipeline    III-5
        Product Introductions                                           III-5
        Strategic Corporate Developments                                III-7
        Focus on Select Players                                         III-10
      B.Market Analytics                                                III-12
        Table 19: US Recent Past, Current & Future Analysis for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-12

        Table 20: US Long-term Projections for Anticoagulants by
        Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-12

        Table 21: US 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-13

  2. Japan                                                              III-14
      A. Market Overview                                                III-14
        Pharmaceutical Industry in Japan                                III-14
         Regulatory Procedure in Japan                                  III-14
         Drug Pricing in Japan                                          III-14
        Anticoagulants Market in Japan                                  III-15
        Rising Incidence of Pulmonary Thromboembolism                   III-15
        Product Introductions                                           III-15
        Strategic Corporate Developments                                III-16
        Mitsubishi Tanabe Pharma Corporation - A Major Player           III-16
      B.Market Analytics                                                III-17
        Table 22: Japanese Recent Past, Current & Future Analysis
        for Anticoagulants by Product Segment - Oral Anticoagulants
        and Injectable Anticoagulants (Unfractionated Heparin and
        Low Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-17

        Table 23: Japanese Long-term Projections for Anticoagulants
        by Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-18

        Table 24: Japanese 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-19

  3. Europe                                                             III-20
      A. Market Overview                                                III-20
        An Analysis of Major Regional Markets                           III-20
         France - A Major Market                                        III-20
         UK - High Growth Potential Market                              III-20
        Pharmaceutical Industry in Europe                               III-20
         Regulatory Procedure in Europe                                 III-20
        Anticoagulants Market in Europe                                 III-21
        List of Patent Protected Anticoagulants in Europe               III-21
         Injectable Sector - Booming Ahead                              III-21
         Market in High Need of an Ideal Therapy                        III-21
        Product Introductions                                           III-22
        Strategic Corporate Development                                 III-22
      B.Market Analytics                                                III-23
        Table 25: European Recent Past, Current & Future Analysis
        for Anticoagulants by Geographic Region/Country - France,
        Germany, Italy, UK, Spain, and Rest of Europe Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-23

        Table 26: European Long-term Projections for Anticoagulants
        by Geographic Region/Country - France, Germany, Italy, UK,
        Spain, and Rest of Europe Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2011
        through 2015 (includes corresponding Graph/Chart)               III-24

        Table 27: European 10-Year Perspective for Anticoagulants by
        Geographic Region - Percentage Breakdown of Dollar Sales for
        France, Germany, Italy, UK, Spain, and Rest of Europe
        Markets for Years 2003, 2008 & 2012 (includes corresponding
        Graph/Chart)                                                    III-25

        Table 28: European Recent Past, Current & Future Analysis
        for Anticoagulants by Product Segment - Oral Anticoagulants
        and Injectable Anticoagulants (Unfractionated Heparin and
        Low Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-26

        Table 29: European Long-term Projections for Anticoagulants
        by Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-27

        Table 30: European 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-27

  3a. France                                                            III-28
      A. Market Overview                                                III-28
        Sanofi-Aventis - A Major Player                                 III-28
      B.Market Analytics                                                III-29
        Table 31: French Recent Past, Current & Future Analysis for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-29

        Table 32: French Long-term Projections for Anticoagulants by
        Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-30

        Table 33: French 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-30

  3b. Germany                                                           III-31
      A. Market Overview                                                III-31
        Market Drivers for Injectable Anticoagulants                    III-31
        Anticoagulants Growth Drive European POC Testing Market         III-31
        Strategic Corporate Developments                                III-31
      B.Market Analytics                                                III-32
        Table 34: German Recent Past, Current & Future Analysis for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-32

        Table 35: German Long-term Projections for Anticoagulants by
        Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-33

        Table 36: German 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-34

  3c. Italy                                                             III-35
       Market Analysis                                                  III-35
        Table 37: Italian Recent Past, Current & Future Analysis for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-35

        Table 38: Italian Long-term Projections for Anticoagulants
        by Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-36

        Table 39: Italian 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-36

  3d. The United Kingdom                                                III-37
      A. Market Overview                                                III-37
        Outlook                                                         III-37
         Growing AF Market for Warfarin                                 III-37
        Select Players                                                  III-37
        Strategic Corporate Developments                                III-38
      B.Market Analytics                                                III-39
        Table 40: UK Recent Past, Current & Future Analysis for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-39

        Table 41: UK Long-term Projections for Anticoagulants by
        Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-40

        Table 42: UK 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-41

  3e. Spain                                                             III-42
       Market Analysis                                                  III-42
        Table 43: Spanish Recent Past, Current & Future Analysis for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2010 (includes corresponding Graph/Chart)               III-42

        Table 44: Spanish Long-term Projections for Anticoagulants
        by Product Segment - Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2011 through 2015
        (includes corresponding Graph/Chart)                            III-43

        Table 45: Spanish 10-Year Perspective for Anticoagulants by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Oral Anticoagulants and Injectable Anticoagulants
        (Unfractionated Heparin and Low Molecular Weight Heparin)
        Markets for the Years 2003, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-44

  3f. Rest of Europe                                                    III-45
       Market Analysis                                                  III-45
        Table 46: Rest of Europe Recent Past, Current & Future
        Analysis for Anticoagulants by Product Segment - Oral
        Anticoagulants and Injectable Anticoagulants (Unfractionated
        Heparin and Low Molecular Weight Heparin) Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-45

        Table 47: Rest of Europe Long-term Projections for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2011
        through 2015 (includes corresponding Graph/Chart)               III-46

        Table 48: Rest of Europe 10-Year Perspective for
        Anticoagulants by Product Segment - Percentage Breakdown of
        Dollar Sales for Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets for the Years 2003, 2008 & 2012
        (includes corresponding Graph/Chart)                            III-47

  4. Rest of World                                                      III-48
      A. Market Overview                                                III-48
        Anticoagulants Market in Australia                              III-48
        Strategic Corporate Developments                                III-48
      B.Market Analytics                                                III-49
        Table 49: Rest of World Recent Past, Current & Future
        Analysis for Anticoagulants by Product Segment - Oral
        Anticoagulants and Injectable Anticoagulants (Unfractionated
        Heparin and Low Molecular Weight Heparin) Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2000 through 2010 (includes corresponding
        Graph/Chart)                                                    III-49

        Table 50: Rest of World Long-term Projections for
        Anticoagulants by Product Segment - Oral Anticoagulants and
        Injectable Anticoagulants (Unfractionated Heparin and Low
        Molecular Weight Heparin) Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2011
        through 2015 (includes corresponding Graph/Chart)               III-50

        Table 51: Rest of World 10-Year Perspective for
        Anticoagulants by Product Segment - Percentage Breakdown of
        Dollar Sales for Oral Anticoagulants and Injectable
        Anticoagulants (Unfractionated Heparin and Low Molecular
        Weight Heparin) Markets for the Years 2003, 2008 & 2012
        (includes corresponding Graph/Chart)                            III-51


 IV. COMPETITIVE LANDSCAPE